Management of CLL in elderly patients asco 2014Jeff Sharman
This document discusses the management of a 86-year-old male patient with chronic lymphocytic leukemia (CLL) who presents with increasing lymphocytosis, lymphadenopathy, and splenomegaly over two years. The patient's fluorescence in situ hybridization (FISH) results show trisomy 12 and unmutated immunoglobulin heavy chain variable region (IgVH). The document reviews treatment options for CLL and evidence from clinical trials regarding chemoimmunotherapy regimens and novel targeted therapies such as ibrutinib, idelalisib, and obinutuzumab. It concludes by recommending obinutuzumab plus chlorambucil as the most appropriate treatment for this fra
Management of untreated cll for web (2015)Jeff Sharman
This represents my current thinking on how to treat patients with previously untreated chronic lymphocytic leukemia. New research changing fast so possibly outdated soon.
Dr. Feroze Momin presents Chronic Lymphocytic Leukemia - Review and new Insights.
To read about Dr. Feroze Momin: http://conquercancers.com/ourdoctorso1.html
To read about Cancer Treatment Center in Michigan:
http://conquercancers.com
The document provides guidelines for the diagnosis, treatment indications, response assessment, and supportive management of chronic lymphocytic leukemia (CLL). It summarizes updates to the understanding of genomic alterations in CLL like TP53 mutations and their prognostic role. It also discusses clinical staging, assessment of organomegaly and lymphadenopathy, response criteria for novel drugs, and monitoring of minimal residual disease. Diagnosis of CLL requires verification through blood smear, immunophenotyping and genetics. Prognostic markers like immunoglobulin variable gene mutational status, cytogenetics, serum markers, and immunophenotype are also covered.
This document describes a case of a 50-year-old male presenting with abdominal discomfort and fever for several months. Examination revealed splenomegaly. Investigations showed elevated white blood cell count with blasts. Bone marrow biopsy demonstrated features of chronic myeloid leukemia in accelerated phase. The patient was positive for the Philadelphia chromosome translocation. The document then provides details on the definition, epidemiology, pathogenesis, classification, clinical features, diagnosis, treatment and prognosis of chronic myeloid leukemia.
Chronic lymphocytic leukemia (CLL) is characterized by the proliferation and accumulation of small, mature lymphocytes in the blood, bone marrow, and lymphoid tissues. CLL is diagnosed based on an absolute lymphocyte count over 5000 with immunophenotyping showing a clonal CD5+/CD19+/CD23+ B-cell population. Prognosis is based on factors like clinical stage, bone marrow histology, lymphocyte doubling time, genetic abnormalities, CD38 and ZAP-70 expression levels, and IgVH mutation status. Treatment options range from watchful waiting to chemotherapy, chemoimmunotherapy, monoclonal antibodies, and stem cell transplantation depending on prognostic factors and symptom severity.
Management of CLL in elderly patients asco 2014Jeff Sharman
This document discusses the management of a 86-year-old male patient with chronic lymphocytic leukemia (CLL) who presents with increasing lymphocytosis, lymphadenopathy, and splenomegaly over two years. The patient's fluorescence in situ hybridization (FISH) results show trisomy 12 and unmutated immunoglobulin heavy chain variable region (IgVH). The document reviews treatment options for CLL and evidence from clinical trials regarding chemoimmunotherapy regimens and novel targeted therapies such as ibrutinib, idelalisib, and obinutuzumab. It concludes by recommending obinutuzumab plus chlorambucil as the most appropriate treatment for this fra
Management of untreated cll for web (2015)Jeff Sharman
This represents my current thinking on how to treat patients with previously untreated chronic lymphocytic leukemia. New research changing fast so possibly outdated soon.
Dr. Feroze Momin presents Chronic Lymphocytic Leukemia - Review and new Insights.
To read about Dr. Feroze Momin: http://conquercancers.com/ourdoctorso1.html
To read about Cancer Treatment Center in Michigan:
http://conquercancers.com
The document provides guidelines for the diagnosis, treatment indications, response assessment, and supportive management of chronic lymphocytic leukemia (CLL). It summarizes updates to the understanding of genomic alterations in CLL like TP53 mutations and their prognostic role. It also discusses clinical staging, assessment of organomegaly and lymphadenopathy, response criteria for novel drugs, and monitoring of minimal residual disease. Diagnosis of CLL requires verification through blood smear, immunophenotyping and genetics. Prognostic markers like immunoglobulin variable gene mutational status, cytogenetics, serum markers, and immunophenotype are also covered.
This document describes a case of a 50-year-old male presenting with abdominal discomfort and fever for several months. Examination revealed splenomegaly. Investigations showed elevated white blood cell count with blasts. Bone marrow biopsy demonstrated features of chronic myeloid leukemia in accelerated phase. The patient was positive for the Philadelphia chromosome translocation. The document then provides details on the definition, epidemiology, pathogenesis, classification, clinical features, diagnosis, treatment and prognosis of chronic myeloid leukemia.
Chronic lymphocytic leukemia (CLL) is characterized by the proliferation and accumulation of small, mature lymphocytes in the blood, bone marrow, and lymphoid tissues. CLL is diagnosed based on an absolute lymphocyte count over 5000 with immunophenotyping showing a clonal CD5+/CD19+/CD23+ B-cell population. Prognosis is based on factors like clinical stage, bone marrow histology, lymphocyte doubling time, genetic abnormalities, CD38 and ZAP-70 expression levels, and IgVH mutation status. Treatment options range from watchful waiting to chemotherapy, chemoimmunotherapy, monoclonal antibodies, and stem cell transplantation depending on prognostic factors and symptom severity.
This document provides an overview of lymphoid leukemias. It begins with an introduction to lymphoid leukemias and compares them to myeloid leukemias. It then discusses the subtypes of acute and chronic lymphoid leukemias in more detail. Key points include distinguishing between B-cell and T-cell acute lymphoblastic leukemias, important genetic alterations in ALL, and initial therapy approaches. Chronic lymphoid leukemias such as CLL are also reviewed, covering topics like diagnostic criteria, prognostic factors, and standard treatment regimens.
This document provides an overview of the myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). It describes key characteristics of each condition, such as increased mature cells in MPNs, decreased blood cells in MDS, and presence of immature cells in AML. Diagnostic criteria and classification systems for AML, including the 2008 WHO classification, are reviewed. Risk stratification in AML and standard treatment approaches are also summarized. Two clinical cases are then presented and discussed in detail.
Chronic myeloid leukemia (CML) is a type of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow. It results from a reciprocal translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, which generates the BCR-ABL fusion gene. This fusion gene encodes for a constitutively active tyrosine kinase that drives the overproduction of white blood cells. CML progresses through chronic, accelerated and blast crisis phases and can be diagnosed by blood and bone marrow tests and identification of the Philadelphia chromosome. Treatment involves tyrosine kinase inhibitors like imatinib, dasatinib or nilotinib, stem cell transplant, or other drugs and monitoring response based on blood counts
Pathogenesis and treatment of Chronic Myeloid LeukemiaAlok Gupta
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome and BCR-ABL fusion gene. The natural history involves chronic, accelerated, and blast crisis phases if untreated. Tyrosine kinase inhibitors (TKIs) like imatinib revolutionized CML treatment by targeting BCR-ABL. TKIs induce high rates of response but resistance and intolerance occur in some patients. For these cases, second-generation TKIs or allogeneic stem cell transplant are recommended. Advanced phase CML has a poorer prognosis but TKIs can induce responses before transplant, which offers the best chance of cure.
This document provides an overview of chronic myeloid leukemia (CML) and its treatment. It discusses prognostic factors in CML, the phases of the disease, and historical treatments including interferon and chemotherapy. It then focuses on current first-line treatments for chronic phase CML, including the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. It reviews clinical trials that have demonstrated the superiority of these targeted therapies compared to historical options. The document concludes with recommendations for monitoring patient response to CML treatments.
Ohio State's 2016 ASH Review - Updates in Myeloproliferative Disorders, inclu...OSUCCC - James
The document discusses updates in the diagnosis and treatment of myeloproliferative disorders and chronic myeloid leukemia. It summarizes long-term data from the COMFORT-II trial showing that ruxolitinib provided durable spleen reductions and potential survival benefit compared to best available therapy in myelofibrosis patients. It also reviews investigational agents being studied for myeloproliferative disorders including pacritinib, which showed consistent efficacy across patient subgroups in the PERSIST-1 trial, and PRM-151, a recombinant human pentraxin-2 that aims to reduce bone marrow fibrosis.
This document provides information on chronic lymphocytic leukemia (CLL), including its definition, diagnosis, incidence, aetiology, clinical features, diagnostic tests, staging systems, prognostic factors, and treatment approaches.
Some key points include:
- CLL is defined as the progressive accumulation of long-lived, functionally incompetent B lymphocytes.
- Diagnosis involves evaluating lymphocyte counts, immunophenotyping, bone marrow biopsy, and cytogenetic/molecular testing.
- Incidence is highest in Western adults over age 65 and is more common in men.
- Prognostic factors include genetic abnormalities, IgV gene mutation status, and response to initial therapy.
- Treatment depends on
Mutations in genes like BCR-ABL, JAK2, MPL, and KIT can cause myeloid neoplasms by promoting proliferation or blocking differentiation. BCR-ABL, found in chronic myeloid leukemia (CML), encodes a fusion protein with constitutive tyrosine kinase activity. The JAK2 V617F mutation is present in the majority of polycythemia vera and a significant portion of essential thrombocythemia and primary myelofibrosis cases. MPL mutations like MPLW515L can also drive essential thrombocythemia and primary myelofibrosis. These genetic abnormalities activate signaling pathways that dysregulate myeloid cell growth and maturation.
This document provides an overview of Chronic Lymphocytic Leukemia (CLL) presented by Dr. Subhash Thakur. It discusses the incidence, clinical features, diagnosis, staging, management and treatment of CLL at different stages. It also covers complications, response evaluation, and long-term implications. CLL most commonly presents with recurring infections in elderly adults. Physical exams may reveal enlarged lymph nodes and splenomegaly. Peripheral blood flow cytometry is most helpful for diagnosis. Watchful waiting is the recommended strategy for asymptomatic early-stage CLL patients.
A case report of a patient with AML who had undergone allogeneic stem call transplantation. She relapsed within 6 months post transplant with lineage switch to ALL. this is follwed by a sfort review of Lineage switch in acute leukemia
This document provides information on Chronic Myeloid Leukemia (CML), including its pathogenesis, diagnosis, staging, and management. It notes that CML is associated with the Philadelphia chromosome containing the BCR-ABL oncogene. Diagnosis involves cytogenetic testing showing the translocation and RT-PCR detecting BCR-ABL copies. CML progresses through chronic, accelerated, and blast crisis phases. First-line treatment is typically imatinib, nilotinib, or dasatinib, with switching to another tyrosine kinase inhibitor or allogeneic stem cell transplant for advanced or resistant disease.
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a translocation between chromosomes 15 and 17, resulting in the PML-RARα fusion gene in leukemic cells. This causes life-threatening coagulopathy and differentiation of promyelocytes into neutrophils in response to all-trans retinoic acid (ATRA). Treatment involves ATRA and chemotherapy, with monitoring for differentiation syndrome as a potential complication. Prognosis depends on initial white blood cell count, with high counts associated with worse outcomes.
01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)Open.Michigan
Slideshow is from the University of Michigan Medical
School's M2 Hematology / Oncology sequence
View additional course materials on Open.Michigan: openmi.ch/med-M2Hematology
This document summarizes a study on kinase-activating lesions in Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL). The study found that 91% of Ph-like ALL cases had genetic alterations activating kinase signaling, with subgroups involving kinases like ABL1, CSF1R, PDGFRB, EPOR, JAK2, CRLF2 and others. Patients with Ph-like ALL had poorer outcomes than those without, and the presence of alterations like IKZF1 deletions conferred even worse prognosis. In vitro experiments showed that fusions involving ABL1, ABL2 and CSF1R were sensitive to tyrosine kinase inhibitors like imatinib and dasatinib.
This document provides an overview of non-small cell lung cancer (NSCLC). It discusses that NSCLC is the leading cause of cancer death, with the majority of cases diagnosed at an advanced stage. Smoking accounts for 90% of lung cancers. Screening trials have shown a 20% reduction in lung cancer mortality with low-dose CT scans. Surgical resection is the main treatment for early stage disease, while chemotherapy, chemoradiation, targeted therapies, and immune checkpoint inhibitors are used for advanced disease based on mutation status and histology. New targeted therapies and immunotherapies have improved outcomes for subsets of NSCLC patients.
Molecular monitoring of CML patients and aims of treatment and management with illustration of the mechanism of action of different drugs (Tyrosine Kinase inhibitors) used in the management of the chronic myeloid leukemia (CML)
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCESRajesh S
The document discusses diagnosis, management, and recent advances in chronic myelogenous leukemia (CML). CML results from a reciprocal translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, which produces the BCR-ABL fusion gene and oncogenic protein. Treatment involves tyrosine kinase inhibitors like imatinib, nilotinib, and dasatinib to inhibit BCR-ABL. Response is monitored through hematologic, cytogenetic, and molecular testing. Resistance can develop through mutations, requiring alternative TKIs or allogeneic stem cell transplant in some cases.
Hairy cell leukemia is a chronic B-cell lymphoproliferative disorder characterized by "hairy" appearing cells. It was first described in the 1950s and primarily affects middle-aged white men. Diagnosis involves identification of characteristic cells in blood and bone marrow samples. Treatment options have evolved over time from splenectomy to purine analogs like cladribine and pentostatin, which achieve high response rates. Rituximab is also effective, especially for relapsed/refractory cases. The goal of treatment is long-term remission and management of symptoms.
This presentation contains all the updated information regarding ongoing treatment protocol, HSCT, Antibiotic prophylaxis, upcoming targeted therapies related to AML
This document discusses a study that compared accounts from doctors and nurses on how they provide emotional care for parents of children with acute lymphoblastic leukemia. The study found that doctors focused on clinical care and explanations of treatment to reassure parents, while nurses relied more on psychological skills and explicit discussion of parents' emotions. Both doctors and nurses saw ensuring emotional care as a team effort rather than the responsibility of individual practitioners.
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Krista Noonan is a medical oncologist specializing in thoracic and genitourinary malignancies at BC Cancer, Surrey Centre. Her research interests focus on thoracic and genitourinary malignancies and health services research. On Thursday, February 27, join Dr. Noonan as she: - Reviews the advancements in systemic therapy in lung cancer over the past decade - Highlights how the advancements in systemic therapy have dramatically improved quality of life and length of life.
View the video: https://youtu.be/3DaUwQ8ab44
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
1) The document discusses response rates and outcomes for patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, nilotinib, and bosutinib.
2) It reports that achieving a major cytogenetic response or deeper molecular response (e.g. MMR) at certain timepoints (e.g. 12 months) on imatinib is associated with improved progression-free and overall survival.
3) For patients who become resistant or intolerant to imatinib, the second-generation TKIs dasatinib, nilotinib and bosutinib have response rates ranging from
This document provides an overview of lymphoid leukemias. It begins with an introduction to lymphoid leukemias and compares them to myeloid leukemias. It then discusses the subtypes of acute and chronic lymphoid leukemias in more detail. Key points include distinguishing between B-cell and T-cell acute lymphoblastic leukemias, important genetic alterations in ALL, and initial therapy approaches. Chronic lymphoid leukemias such as CLL are also reviewed, covering topics like diagnostic criteria, prognostic factors, and standard treatment regimens.
This document provides an overview of the myeloid malignancies, including myeloproliferative neoplasms (MPNs), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). It describes key characteristics of each condition, such as increased mature cells in MPNs, decreased blood cells in MDS, and presence of immature cells in AML. Diagnostic criteria and classification systems for AML, including the 2008 WHO classification, are reviewed. Risk stratification in AML and standard treatment approaches are also summarized. Two clinical cases are then presented and discussed in detail.
Chronic myeloid leukemia (CML) is a type of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow. It results from a reciprocal translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, which generates the BCR-ABL fusion gene. This fusion gene encodes for a constitutively active tyrosine kinase that drives the overproduction of white blood cells. CML progresses through chronic, accelerated and blast crisis phases and can be diagnosed by blood and bone marrow tests and identification of the Philadelphia chromosome. Treatment involves tyrosine kinase inhibitors like imatinib, dasatinib or nilotinib, stem cell transplant, or other drugs and monitoring response based on blood counts
Pathogenesis and treatment of Chronic Myeloid LeukemiaAlok Gupta
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the Philadelphia chromosome and BCR-ABL fusion gene. The natural history involves chronic, accelerated, and blast crisis phases if untreated. Tyrosine kinase inhibitors (TKIs) like imatinib revolutionized CML treatment by targeting BCR-ABL. TKIs induce high rates of response but resistance and intolerance occur in some patients. For these cases, second-generation TKIs or allogeneic stem cell transplant are recommended. Advanced phase CML has a poorer prognosis but TKIs can induce responses before transplant, which offers the best chance of cure.
This document provides an overview of chronic myeloid leukemia (CML) and its treatment. It discusses prognostic factors in CML, the phases of the disease, and historical treatments including interferon and chemotherapy. It then focuses on current first-line treatments for chronic phase CML, including the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. It reviews clinical trials that have demonstrated the superiority of these targeted therapies compared to historical options. The document concludes with recommendations for monitoring patient response to CML treatments.
Ohio State's 2016 ASH Review - Updates in Myeloproliferative Disorders, inclu...OSUCCC - James
The document discusses updates in the diagnosis and treatment of myeloproliferative disorders and chronic myeloid leukemia. It summarizes long-term data from the COMFORT-II trial showing that ruxolitinib provided durable spleen reductions and potential survival benefit compared to best available therapy in myelofibrosis patients. It also reviews investigational agents being studied for myeloproliferative disorders including pacritinib, which showed consistent efficacy across patient subgroups in the PERSIST-1 trial, and PRM-151, a recombinant human pentraxin-2 that aims to reduce bone marrow fibrosis.
This document provides information on chronic lymphocytic leukemia (CLL), including its definition, diagnosis, incidence, aetiology, clinical features, diagnostic tests, staging systems, prognostic factors, and treatment approaches.
Some key points include:
- CLL is defined as the progressive accumulation of long-lived, functionally incompetent B lymphocytes.
- Diagnosis involves evaluating lymphocyte counts, immunophenotyping, bone marrow biopsy, and cytogenetic/molecular testing.
- Incidence is highest in Western adults over age 65 and is more common in men.
- Prognostic factors include genetic abnormalities, IgV gene mutation status, and response to initial therapy.
- Treatment depends on
Mutations in genes like BCR-ABL, JAK2, MPL, and KIT can cause myeloid neoplasms by promoting proliferation or blocking differentiation. BCR-ABL, found in chronic myeloid leukemia (CML), encodes a fusion protein with constitutive tyrosine kinase activity. The JAK2 V617F mutation is present in the majority of polycythemia vera and a significant portion of essential thrombocythemia and primary myelofibrosis cases. MPL mutations like MPLW515L can also drive essential thrombocythemia and primary myelofibrosis. These genetic abnormalities activate signaling pathways that dysregulate myeloid cell growth and maturation.
This document provides an overview of Chronic Lymphocytic Leukemia (CLL) presented by Dr. Subhash Thakur. It discusses the incidence, clinical features, diagnosis, staging, management and treatment of CLL at different stages. It also covers complications, response evaluation, and long-term implications. CLL most commonly presents with recurring infections in elderly adults. Physical exams may reveal enlarged lymph nodes and splenomegaly. Peripheral blood flow cytometry is most helpful for diagnosis. Watchful waiting is the recommended strategy for asymptomatic early-stage CLL patients.
A case report of a patient with AML who had undergone allogeneic stem call transplantation. She relapsed within 6 months post transplant with lineage switch to ALL. this is follwed by a sfort review of Lineage switch in acute leukemia
This document provides information on Chronic Myeloid Leukemia (CML), including its pathogenesis, diagnosis, staging, and management. It notes that CML is associated with the Philadelphia chromosome containing the BCR-ABL oncogene. Diagnosis involves cytogenetic testing showing the translocation and RT-PCR detecting BCR-ABL copies. CML progresses through chronic, accelerated, and blast crisis phases. First-line treatment is typically imatinib, nilotinib, or dasatinib, with switching to another tyrosine kinase inhibitor or allogeneic stem cell transplant for advanced or resistant disease.
Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia characterized by a translocation between chromosomes 15 and 17, resulting in the PML-RARα fusion gene in leukemic cells. This causes life-threatening coagulopathy and differentiation of promyelocytes into neutrophils in response to all-trans retinoic acid (ATRA). Treatment involves ATRA and chemotherapy, with monitoring for differentiation syndrome as a potential complication. Prognosis depends on initial white blood cell count, with high counts associated with worse outcomes.
01.13.09: Chronic Myeloid Leukemia and other Myeloproliferative Neoplasms (MPNs)Open.Michigan
Slideshow is from the University of Michigan Medical
School's M2 Hematology / Oncology sequence
View additional course materials on Open.Michigan: openmi.ch/med-M2Hematology
This document summarizes a study on kinase-activating lesions in Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL). The study found that 91% of Ph-like ALL cases had genetic alterations activating kinase signaling, with subgroups involving kinases like ABL1, CSF1R, PDGFRB, EPOR, JAK2, CRLF2 and others. Patients with Ph-like ALL had poorer outcomes than those without, and the presence of alterations like IKZF1 deletions conferred even worse prognosis. In vitro experiments showed that fusions involving ABL1, ABL2 and CSF1R were sensitive to tyrosine kinase inhibitors like imatinib and dasatinib.
This document provides an overview of non-small cell lung cancer (NSCLC). It discusses that NSCLC is the leading cause of cancer death, with the majority of cases diagnosed at an advanced stage. Smoking accounts for 90% of lung cancers. Screening trials have shown a 20% reduction in lung cancer mortality with low-dose CT scans. Surgical resection is the main treatment for early stage disease, while chemotherapy, chemoradiation, targeted therapies, and immune checkpoint inhibitors are used for advanced disease based on mutation status and histology. New targeted therapies and immunotherapies have improved outcomes for subsets of NSCLC patients.
Molecular monitoring of CML patients and aims of treatment and management with illustration of the mechanism of action of different drugs (Tyrosine Kinase inhibitors) used in the management of the chronic myeloid leukemia (CML)
CML - DIAGNOSIS,MANAGEMENT AND RECENT ADVANCESRajesh S
The document discusses diagnosis, management, and recent advances in chronic myelogenous leukemia (CML). CML results from a reciprocal translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, which produces the BCR-ABL fusion gene and oncogenic protein. Treatment involves tyrosine kinase inhibitors like imatinib, nilotinib, and dasatinib to inhibit BCR-ABL. Response is monitored through hematologic, cytogenetic, and molecular testing. Resistance can develop through mutations, requiring alternative TKIs or allogeneic stem cell transplant in some cases.
Hairy cell leukemia is a chronic B-cell lymphoproliferative disorder characterized by "hairy" appearing cells. It was first described in the 1950s and primarily affects middle-aged white men. Diagnosis involves identification of characteristic cells in blood and bone marrow samples. Treatment options have evolved over time from splenectomy to purine analogs like cladribine and pentostatin, which achieve high response rates. Rituximab is also effective, especially for relapsed/refractory cases. The goal of treatment is long-term remission and management of symptoms.
This presentation contains all the updated information regarding ongoing treatment protocol, HSCT, Antibiotic prophylaxis, upcoming targeted therapies related to AML
This document discusses a study that compared accounts from doctors and nurses on how they provide emotional care for parents of children with acute lymphoblastic leukemia. The study found that doctors focused on clinical care and explanations of treatment to reassure parents, while nurses relied more on psychological skills and explicit discussion of parents' emotions. Both doctors and nurses saw ensuring emotional care as a team effort rather than the responsibility of individual practitioners.
Don't miss our upcoming webinars: Subscribe today!
In this webinar:
Dr. Krista Noonan is a medical oncologist specializing in thoracic and genitourinary malignancies at BC Cancer, Surrey Centre. Her research interests focus on thoracic and genitourinary malignancies and health services research. On Thursday, February 27, join Dr. Noonan as she: - Reviews the advancements in systemic therapy in lung cancer over the past decade - Highlights how the advancements in systemic therapy have dramatically improved quality of life and length of life.
View the video: https://youtu.be/3DaUwQ8ab44
To learn more about CCSN, visit us at survivornet.ca
Follow CCSN on social media:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Instagram: https://www.instagram.com/survivornet_ca/
Pinterest - https://www.pinterest.com/survivornetwork
1) The document discusses response rates and outcomes for patients with chronic myeloid leukemia (CML) treated with various tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, nilotinib, and bosutinib.
2) It reports that achieving a major cytogenetic response or deeper molecular response (e.g. MMR) at certain timepoints (e.g. 12 months) on imatinib is associated with improved progression-free and overall survival.
3) For patients who become resistant or intolerant to imatinib, the second-generation TKIs dasatinib, nilotinib and bosutinib have response rates ranging from
The document discusses guidelines for colposcopy in the UK and critiques current approaches. It notes that UK guidelines are developed by the NHS Cervical Screening Programme through multi-disciplinary consensus, without formal literature reviews or grading of evidence levels. With the introduction of primary HPV screening, future guidelines will need revision to minimize unnecessary referrals and interventions while ensuring proper treatment and follow up of precancerous lesions. Key open questions include what risk thresholds warrant colposcopy referral and how to stratify management based on HPV genotype. Overall, there remains a lack of high-quality evidence to inform standardized colposcopy practices.
DOUBLE HIT AND OTHER MOLECULARLY DEFINED LARGE CELL LYMPHOMASspa718
This document summarizes key information about double hit lymphomas and other molecularly defined large B-cell lymphomas. It discusses how approximately 40% of B-cell lymphomas involve chromosomal translocations involving oncogenes like MYC and BCL2. "Double hit" lymphomas specifically involve recurrent breakpoints activating both MYC and another oncogene like BCL2. These double hit lymphomas have a poor prognosis when treated with standard R-CHOP chemotherapy and intensive chemotherapy regimens or stem cell transplantation may have better outcomes. Ongoing clinical trials are exploring new treatment approaches for these high-risk lymphomas.
This document summarizes key information about double hit lymphomas and other molecularly defined large B-cell lymphomas. It discusses how approximately 40% of B-cell lymphomas involve chromosomal translocations involving oncogenes like MYC and BCL2. Double hit lymphomas specifically involve recurrent breakpoints activating both MYC and another oncogene like BCL2. These tumors have a germinal center B-cell phenotype and poor response to standard R-CHOP chemotherapy, with median survival usually less than 1 year. More intensive chemotherapy regimens like dose-adjusted EPOCH show promise but prospective clinical trials are still needed to determine optimal treatment approaches for these high-risk lymphomas.
DOUBLE HIT AND OTHER MOLECULARLY DEFINED LARGE CELL LYMPHOMASspa718
This document summarizes key information about double hit lymphomas and other molecularly defined large B-cell lymphomas. It discusses how approximately 40% of B-cell lymphomas involve chromosomal translocations involving oncogenes like MYC and BCL2. Double hit lymphomas specifically involve recurrent breakpoints activating both MYC and another oncogene like BCL2. These tumors have a germinal center B-cell phenotype and poor response to standard R-CHOP chemotherapy, with median survival usually less than 1 year. More intensive chemotherapy regimens like dose-adjusted EPOCH show promise for improving outcomes in double hit lymphoma and other MYC-rearranged large B-cell lymphomas.
This document discusses the management of triple negative breast cancer (TNBC). It begins with an overview of the three main subtypes of breast cancer and their associated treatments. It then focuses on the characteristics and treatment challenges of TNBC, including its aggressiveness, younger patient population, and lack of targeted therapies. Current treatment options for metastatic TNBC are discussed, including various chemotherapy regimens. The document also touches on neoadjuvant and adjuvant systemic therapy approaches as well as ongoing research into better understanding the biology of TNBC to revolutionize outcomes.
(Ohio State's 2016 ASH Review) ASH 2015 REVIEW – LYMPHOMA ABSTRACTSOSUCCC - James
This document summarizes key abstracts presented at the American Society of Hematology (ASH) 2015 conference related to lymphoma subtypes including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and Hodgkin's lymphoma (HL). For MCL, abstracts showed that bortezomib maintenance after immunochemotherapy and stem cell transplant improved progression-free survival compared to consolidation or historical controls. Pre-transplant treatment with R-bendamustine induced high rates of minimal residual disease negativity associated with improved outcomes. For DLBCL, adding bortezomib to R-CHOP in non-germinal center subtype showed improved response rates
This document provides guidelines for the treatment of chronic myeloid leukemia (CML) based on a panel of 34 experts. It summarizes the diagnostic workup, epidemiology, prognostic factors, response monitoring and definitions, and treatment recommendations for CML. The first-line treatment involves tyrosine kinase inhibitors like imatinib, nilotinib, dasatinib or bosutinib. For patients who are resistant or intolerant to first-line treatment, second-line TKIs or allogeneic stem cell transplantation may be considered. The goal of treatment is to achieve a deep molecular response and possibly treatment-free remission in some patients.
This document summarizes information about Hodgkin's and non-Hodgkin's lymphoma, including:
- Hodgkin's lymphoma accounts for about 30% of malignant lymphomas and is typically treated initially with ABVD chemotherapy plus radiation therapy. Non-Hodgkin's lymphoma is more common and heterogeneous.
- For advanced Hodgkin's lymphoma, BEACOPP chemotherapy is more effective than COPP/ABVD but also more toxic, increasing risks of infertility, premature menopause, and leukemia.
- Long-term survivors of Hodgkin's lymphoma face elevated risks of secondary cancers decades later due to effects of treatment.
This document summarizes updates from clinical trials studying treatment-free remission in chronic myeloid leukemia patients. It discusses reasons to stop tyrosine kinase inhibitor treatment, results from major trials like STIM1 and ENESTfreedom showing 42-50% of patients remain in remission 1-5 years after stopping treatment. Key factors for successful treatment cessation include sustained deep molecular response for multiple years. The document outlines safety and predictive factors as well as future research directions in working towards potentially curing CML.
Perrotti A.P. From empiric therapy to guide lines of silent and aggressive li...Gianfranco Tammaro
This document summarizes treatment approaches for non-Hodgkin lymphomas over time:
1. Prior to 1997, treatment included surgery, watchful waiting for indolent lymphomas, radiotherapy for stage I disease, and polychemotherapy. Chemotherapy regimens like CHOP became the standard.
2. After 1997, immunotherapy was introduced with monoclonal antibodies like rituximab, improving response rates and survival. Rituximab combined with chemotherapy became the standard first-line treatment for B-cell lymphomas.
3. Recent studies are exploring new drug combinations, such as lenalidomide and rituximab for untreated indolent lymphomas, which achieved high response rates
Best of ASCO Metastatic Non-Small Cell Lung CancerH. Jack West
Dr. Jack West's presentation on highlights in advanced non-small cell lung cancer from ASCO 2014, focusing on new agents ramucirumab and necitumumab for broad NSCLC populations, crizotinib and ceritinib for ALK-positive NSCLC, EGFR inhibitor-options of afatinib and bevacizumab added to erlotinib for first line treatment of EGFR mutation-positive NSCLC, and AZD9291 or CO1686 for EGFR mutation-positive patients with acquired resistance.
This document summarizes prognostic factors and treatment approaches for follicular lymphoma. Some key points:
- Prognostic factors include age, histologic grade, FLIPI score, gene expression profiling, and metabolic tumor volume on PET scans.
- First-line treatment for symptomatic advanced disease is usually rituximab plus chemotherapy such as bendamustine, followed by rituximab maintenance for 2 years.
- The PRIMA trial showed improved progression-free survival with 2 years of rituximab maintenance compared to observation alone in patients achieving response to first-line treatment.
- The GALLIUM trial found improved progression-free survival for first-line treatment of follicular
When to stop TKI in Chronic Myelogenous Leukemia?spa718
This document discusses when to stop tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) patients. There are three situations when TKI treatment may be stopped: 1) when the TKIs are no longer effective, 2) when the TKIs become too toxic, and 3) when a complete molecular response (CMR) has been achieved, indicating the TKIs appear to have cured the disease. Achieving an undetectable minimal residual disease (UMRD) state, with no detectable BCR-ABL mRNA, is associated with a low relapse risk. Some CML patients are able to stop TKI treatment long-term after achieving a UMRD, but stopping treatment
1. ABVD remains the standard first-line treatment for Hodgkin's lymphoma as it obtains similar survival results to other regimens but is less toxic.
2. For aggressive NHL, an interim positive PET scan after 2 cycles of chemotherapy is not necessarily predictive of treatment efficacy and should not be used to guide treatment.
3. In follicular lymphoma, watch-and-wait is an option for early stage disease but single agent rituximab may allow more patients to avoid chemotherapy compared to watch-and-wait.
This document discusses lung cancer screening guidelines and recommendations. It begins with a case study of a 76-year-old male smoker diagnosed with stage IA lung cancer through low-dose CT screening. It then reviews the epidemiology of lung cancer, findings from the National Lung Screening Trial demonstrating a 20% reduction in lung cancer mortality with low-dose CT screening, and current guidelines for lung cancer screening from organizations like the USPSTF. It emphasizes that tobacco cessation is the most effective way to reduce lung cancer risk and maximize the benefits of screening.
This document provides information about Dr. Jason Westin, an assistant professor at MD Anderson Cancer Center whose research focuses on improving therapy and outcomes for patients with lymphoma. His specific research interests include diffuse large B-cell lymphoma, developing systems to identify optimal therapeutic combinations for individual patients, drug synergy and antagonism, scale free networks in cancer therapy, and developing sensitive disease monitoring methods. The document also summarizes several of Dr. Westin's presentations on novel targeted therapies in T-cell lymphoma from 2014, including studies on drugs such as brentuximab, mogamulizumab, lenalidomide, alisertib, selinexor, romidepsin, panobinostat, and inhibitors of the
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Adhd Medication Shortage Uk - trinexpharmacy.comreignlana06
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kol...rightmanforbloodline
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Versio
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
TEST BANK For An Introduction to Brain and Behavior, 7th Edition by Bryan Kolb, Ian Q. Whishaw, Verified Chapters 1 - 16, Complete Newest Version
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
1. CLL: Past, Present, and Future
Jeff Sharman M.D.
Medical Director Hematology Research
US Oncology
http://cll-nhl.com
2. CLL: Management in a TKI World
•
•
•
•
•
Historical perspectives
FCR – The rise and fall
Choosing first line therapy in 2014
Management of relapsed disease
Ibrutinib considerations
3. CLL: Management in a TKI World
•
•
•
•
•
Historical perspectives
FCR – The rise and fall
Choosing first line therapy in 2014
Management of relapsed disease
Ibrutinib considerations
15. Patterns of Care (FCR in Front Line)
• Age < 65 = 45% FCR
• Age 65-75 = 32% FCR
• Age > 75 = 20% FCR
16. Clinical trials versus real life
• MDA FCR Median Age
– 57 years old
• German CLL8 (FC vs FCR)
– 61 years old
• Real life
– Age 71 at diagnosis
– Age 74 at first treatment
17. Age Matters
• Decreased Renal Function
– Clears fludarabine
• Decreased Marrow Reserves
– Prolonged cytopenias
– MDS / AML
• Infectious Complications
– Really nasty gross stuff
19. Death within 12 months of first line
therapy
• MDA = 1%
• German CLL8/10 study = 3-4%
• Registry Studies = 10%
20. Case Study
• 72 year old retired lumber yard worker
– Lymphocytosis c/w CLL stage I, but over 2 years progressive
adenopathy and hemoglobin down to 10
– Deletion 13q but unmutated IgVH
• Entered onto FCR vs PCR study
– Stopped FCR after cycle 3 due to myelotoxicity
– Has maintained remission for six years
• Multiple treatment complications
– Pulmonary aspergillosis
– Received > 50 units PRBC’s over next two years
– Now has MDS
21. Where will FCR fit in the next five years?
”We’re
going to
get rid of
FCR”
22.
23. German CLL10 Study
FCR versus BR
CIRS < 7, Creatinine Clearance > 70, no 17P deletion
FCR
BR
ORR
97.8%
97.8%
CR
47%
38%
MRD Negative
71%
66%
2 Year PFS
85%
78%
24. German CLL10 Study
FCR versus BR
CIRS < 7, Creatinine Clearance > 70, no 17P deletion
FCR
BR
G3/4 Neutropenia
82%
56%
G3/4 Infection
47%
26%
Induction Death
4%
2%
Complete 6 cycles
70%
80%
25. CLL10 Summary
• FCR works a little better, but considerably
more toxic than BR
• No clear winner as gains in response offset by
increased toxicity
29. CLL: Management in a TKI World
•
•
•
•
•
Historical perspectives
FCR – The rise and fall
Choosing first line therapy in 2014
Management of relapsed disease
Ibrutinib considerations
31. CLL: Management in a TKI World
•
•
•
•
•
Historical perspectives
FCR – The rise and fall
Choosing first line therapy in 2014
Management of relapsed disease
Ibrutinib considerations
40. CLL – Evolution in Real Time
A: Pre-Chlorambucil
B: Pre FCR
C: Post FCR
D: Pre Ofatumumab
E: Post Ofatumumab
41. CLL: Management in a TKI World
•
•
•
•
•
Historical perspectives
FCR – The rise and fall
Choosing first line therapy in 2014
Management of relapsed disease
Ibrutinib considerations
42. Clinical Challenges
• Initial lymphocytosis
• Interruptions (surgery / other)
• Adherence
• Copayments
• Adventures in medical decision making
• Progressions
43. Clinical Challenges
• Initial lymphocytosis
• Interruptions (surgery / other)
• Adherence
• Copayments
• Adventures in medical decision making
• Progressions